Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends

Area of Science:

• Urology
• Oncology
• Medical Science

Background:

• Prostate carcinoma is a common, diverse cancer often linked to elevated prostate-specific antigen (PSA).
• Castration-resistant prostate cancer (CRPC) is heterogeneous, ranging from asymptomatic PSA elevation to rapidly progressive disease.
• Nonmetastatic CRPC (nmCRPC) is a transitional phase where most patients eventually develop metastases.

Purpose of the Study:

• To address current challenges in managing nonmetastatic castration-resistant prostate cancer (nmCRPC).
• To discuss advancements in diagnostic imaging and prognostic classification.
• To explore strategies for selecting optimal treatments amidst disease heterogeneity and patient comorbidities.

Main Methods:

• Review of current literature on nmCRPC diagnosis, prognosis, and treatment.
• Analysis of factors influencing disease progression, such as age, Gleason score, PSA levels, PSA doubling time, and alkaline phosphatase.
• Discussion of evolving imaging modalities and their impact on early detection and classification.

Main Results:

• nmCRPC management is complex due to significant disease heterogeneity.
• New imaging techniques improve disease detection and staging.
• Traditional prognostic factors like PSA doubling time may oversimplify disease aggressiveness.

Conclusions:

• Accurate diagnosis and prognostic classification are critical for effective nmCRPC management.
• Balancing treatment efficacy with toxicity is essential, especially in patients with comorbidities.
• Further research is needed to fully understand disease heterogeneity and refine treatment selection for nmCRPC patients.